Advanced Filters
noise

osteopenia Clinical Trials

A listing of osteopenia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 176 clinical trials

Preserving Geriatric Muscle With an Osteoporosis Medication

Our goal is to demonstrate efficacy of the novel agent Denosumab to improve or preserve muscle health, strength, mobility and function in frail older adults.

65 years of age All Phase 4
C ChienYu Huang, Bachelor

Effects of Liposomal Encapsulation on Calcium Powder Absorption and Metabolism

Compared with traditional calcium supplements, liposome calcium can increase the bioavailability of calcium and reduce the waste caused by gastric acid destruction of calcium. This allows calcium to be released slowly in the intestines, reducing the risk of indigestion or other side effects caused by excessive intake at one time. …

20 - 60 years of age All Phase N/A
J Jiaxian Wang, MD,PhD

Intravenous Infusion of hMSC100 (hUC-MSC) in Postmenopausal Women With Osteoporosis at High Risk of Fracture

The primary objective of this study is to evaluate the safety and tolerability of human umbilical cord-derived mesenchymal stem cells for injection (hMSC100) in postmenopausal women with osteoporosis who are at high risk of fracture.

45 - 85 years of age Female Phase 1

Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China

The primary objective of this study is to evaluate the efficacy of Prolia on lumbar spine BMD at 12 months.

30 - 90 years of age Male Phase 4

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

People with Alzheimer's disease are at an increased risk of bone fracture. Some studies have shown that those taking donepezil have a lower rate of bone fractures, but the reasons for this are unknown. The purpose of this study is to measure the effect of donepezil treatment on bone metabolism …

50 years of age All Phase 2
A Ashley Shoemaker, MD

Theophylline Treatment for Pseudohypoparathyroidism

Pseudohypoparathyroidism is a genetic disorder with limited treatment options. Patients have early-onset obesity, short stature and increased risk of type 2 diabetes. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. The investigators hypothesize that theophylline will cause weight loss, improve glucose tolerance …

13 - 99 years of age All Phase 2
A Amita Sharma

Effect of Theophylline in Pseudohypoparathyroidism

The study evaluates the effect of theophylline in 100 subjects with Pseudohypoparathyroidism.

5 - 21 years of age All Phase 4
a antimo moretti

Functional and Metabolic Effects of Fonte Fausta® Water on Bone and Muscle Health in Osteoporotic Patients

This clinical study investigates the effects of Fonte Fausta® water on bone and muscle metabolism, as well as quality of life, in patients with osteoporosis or osteopenia, with or without sarcopenia. Conducted as a multicenter, triple-arm trial, it evaluates functional and biochemical markers over 12 months. Patients are randomized into …

65 years of age All Phase N/A
H Hartmut H Malluche, MD

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

Osteoporosis affects 24.5% of women over 65 and results in fracture-related hospital admissions exceeding those of heart attacks, strokes and breast cancer combined. Current treatment options do not account for differences between age-related and estrogen deficiency related osteoporosis, because of the need for bone biopsies for determination. This study will …

40 years of age All Phase 4
S Sudeepa Bhattacharya, MPA

EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

Proton pump inhibitors (PPIs) are widely used for the control of gastric ulcer-gastritis, erosive esophagitis (gastroesophageal reflux disease), peptic ulcer disease (duodenal ulcer), and heartburn. Despite their efficacy, their use has been implicated in possibly causing fragility fractures (osteoporosis), hypomagnesemia (magnesium deficiency) and increased risk of chronic kidney disease (CKD). …

21 - 99 years of age All Phase 3

Simplify language using AI